ReNeuron Group’s (RENE.L) interim results announcement provided no surprises on the financial front, but the commentary on its conference presentation on the expanded tissue-targeting properties of the CustomEX™ exosome platform far exceeded our expectations. The shop-window presentation is hoped to gee up partners in the time before its cash runway is exhausted, but other funding options remain.
